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Abstract
Introduction: Our purpose was to test the hypothesis that hyperuricemia is associated with coronary artery
calcification (CAC) among a relatively healthy population, and that the extent of calcification is directly proportional
to the serum uric acid (sUA) concentration.
Methods: Data from 2,498 participants in the Coronary Artery Risk Development in Young Adults (CARDIA) study
were analyzed using logistic regression models. Subjects were free of clinical heart disease, diabetes, and renal
impairment. The main measure was the presence of any CAC by computerized tomography (Agatston score >0).
Results: Forty-eight percent of the study participants were male and 45% were African-American. Mean (± SD) age
was 40 ± 4 years, body mass index 28 ± 6 kg/m
2, Framingham risk score -0.7 ± 5%, blood pressure 113 ± 14/75 ±
11 mmHg, alcohol consumption 12 ± 27 ml/day, and sUA 297 ± 89 μmol/L (5.0 ± 1.5 mg/dL). Prevalence of CAC
increased with sUA concentration among both men and women. Adjusted for age, gender, race, lipoproteins,
triglycerides, smoking, blood pressure, presence of metabolic syndrome, C-reactive protein, waist circumference,
alcohol use, creatinine, and serum albumin, the highest quartile of sUA (>393 μmol/L [6.6 mg/dL] for men and
>274 μmol/L [4.6 mg/dL] for women) was associated with an odds ratio of 1.87 (1.19-2.93) compared to the lowest
quartile (<291 μmol/L [4.9 mg/dL] for men and <196 μmol/L [3.3 mg/dL] for women). Among those with any CAC,
each unit increase in sUA was associated with a 22% increase in Agatston score (P = 0.008) after adjusting for the
above covariates.
Conclusions: Hyperuricemia is an independent risk factor for subclinical atherosclerosis in young adults.
Introduction
Although the link between elevated serum uric acid
(sUA) concentrations and the risk for atherosclerotic car-
diovascular and cerebrovascular disease has long been
observed, only recently have the pathophysiologic links
become clearer [1]. Kanbay and colleagues [2] recently
summarized the emerging data suggesting that hyperuri-
cemia may cause not only atherosclerosis in the macro-
vascular beds such as the coronaries and the carotids but
also microvascular damage in the renal vascular bed and
may exacerbate vascular disease.
Almost all epidemiological studies performed in popula-
tions of higher-than-normal risk have shown a consistent
association between sUA and coronary artery disease
(CAD) [1]. Studies on the lower-than-normal-risk popula-
tions that have relatively few events need to have a very
large sample size to be able to measure the magnitude of
relative risks observed in the high-risk groups (relative risk
of 1.5 to 2.5). In such a context, markers of subclinical
atherosclerosis are important outcomes to examine. The
detection of coronary artery calcification (CAC) by ultrafast
computed tomography (CT) scanning is highly predictive
of the presence of histopathologic atherosclerosis [3], and
the extent of calcification correlates well with plaque bur-
den [4]. It is also an accurate (positive predictive value of
84% to 96%) measure of obstructive CAD compared with
angiographic evaluation and is a useful tool to study subcli-
nical CAD, especially in population settings [5]. Some
argue that, in the setting of observational studies, CAC
measurement may even be superior to other measures
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ovascular outcomes [6].
The primary objective of this epidemiological study
was to understand the relationship between sUA con-
centration and CAC in relatively young and healthy
adults. If the hyperuricemia-CAD link is real, we can
expect that the prevalence of CAC among those with
higher sUA levels will be greater and that the extent of
CAC will be directly proportional to the degree of
hyperuricemia - a hypothesis that we tested here.
Materials and methods
Design
We performed cross-sectional analyses of year-15 data
from the Coronary Artery Risk Development in Young
Adults (CARDIA) study, a prospective observational
cohort study of 5,115 subjects recruited between the ages
of 18 and 30 years and followed for 15 years. Ethical
approval for the CARDIA study was obtained from parti-
cipating institutions, and informed consent was obtained
from the patients.
Setting, participants, and follow-up
The CARDIA study is an ongoing multicenter cohort
study based at four centers: Chicago, IL; Birmingham,
AL; Minneapolis, MN; and Oakland, CA. The observa-
tion baseline of this study was 1985-1986, when all parti-
cipants were recruited and enrolled. The cohort had
approximately equal numbers of African-Americans and
whites, men and women, adults 18 to 24 years old and 25
to 30 years old, and participants with more than and less
than high school education [7]. Subsequently, they were
followed up at years 2, 5, 7, 10, 15, and 20. A detailed
description of the study methodology has been published
[7]. At baseline and every follow-up visit, CARDIA study
participants underwent extensive medical examinations
with a specific focus on cardiovascular risk factors. The
study provided detailed information on demographic
characteristics and on lifestyle habits such as alcohol con-
sumption and smoking.
Inclusion and exclusion criteria
We studied the data collected during year 15 of this pro-
spective study, at which time all participants were invited
to obtain an electron beam computerized tomography
(EBCT) scan. We excluded all participants with missing
values for CAC scores or sUA concentrations and any
self-reported coronary heart disease, including angina
symptoms. Since diabetes is associated with both higher
sUA concentration and higher incidence rates of CAC
[8], we excluded all subjects with type 2 diabetes or pre-
diabetes (defined by American Diabetes Association cri-
teria [9]) and those who reported the use of diabetes
medications or a physician diagnosis of diabetes. Since
the presence of renal impairment can affect sUA concen-
tration and atherosclerosis, individuals with an estimated
glomerular filtration rate of less than 60 mL/minute per
1.73 m
2 (calculated by the Modification of Diet in Renal
Disease equation) were also excluded [10].
Coronary artery calcification measurement, case
definition, and rationale
In a single session, two CT scans were obtained at year 15
for each participant by using an EBCT scanner (Imatron
C-150™; GE Medical Systems, Milwaukee, WI [Chicago
and Oakland centers]) or a multidetector CT scanner (GE
Lightspeed™; GE Medical Systems [Birmingham center]
or Volume Zoom™;S i e m e n s ,E r l a n g e n ,G e r m a n y[ M i n -
neapolis center]). Details of the CT protocol have been
published [11]. The amount of CAC can be measured to
provide a reasonable estimate of total coronary atheroma,
including calcified and non-calcified plaque. Coronary cal-
cium assessments for diagnosis of atherosclerosis and
obstructive disease and for risk stratification for future car-
diac events have undergone significant validation over the
past 20 years [12,13]. The extent of calcification was quan-
tified by using the Agatston method, in which total cal-
cium scores were calculated on the basis of the number,
areas, and peak Hounsfield computed tomographic num-
bers of the calcific lesions [4]. A previous study showed
that an Agatston score of zero indicates no identifiable
plaque with a negative predictive value of 98% for those 40
to 49 years old, an age group similar to that of our cohort
[4]. In angiographic studies done in older populations,
scores of 1 to 99 indicate mild plaque, 100 to 399 moder-
ate plaque, and at least 400 severe atherosclerotic plaque
burden. Given that our goal was to assess for any CAC in
young adults with no clinical evidence of CAD, we defined
CAC as any positive, non-zero Agatston score, using the
average of two scans. Each scan with at least one non-zero
score (n = 350, 11.5%) was reviewed by an expert investi-
gator who was blinded to the scan scores to verify CAC
presence. The agreement between scans was high (kappa
= 0.79, 95% confidence interval [CI] 0.75 to 0.83), and dis-
cordance was only 3.6% [14].
Serum uric acid
Fasting concentration of sUA was measured in a central
l a b o r a t o r yb yu s i n gac o l o r i m e t r i ca s s a yw i t hr i g o r o u s
quality control.
Statistical analyses
Our primary outcome measure was subclinical athero-
sclerosis, defined as the presence of CAC by CT scan.
Several cutoff points ranging from 0 to 1,000 have been
used in other studies to define the presence of CAC,
depending on its prevalence. We assessed the CT
images for evidence of any CAC (defined as Agatston
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mild plaque (Agatston score of greater than 10). The
choice of these cutoffs was dictated by the statistical dis-
tribution of Agatston score in our young population.
The first objective was to examine the relationship
between measures of subclinical atherosclerosis and
s U A( a sac o n t i n u o u sa sw e l la sas t r a t i f i e dm e a s u r e ) .
These analyses were performed by using logistic regres-
sion models in which presence or absence of CAC
(defined as an Agatston score of greater than 0 or
greater than 10) was the dependent variable and sUA
was the independent variable of interest. sUA quartiles
were defined for men and women separately and were
subsequently pooled.
We adjusted for the following covariates measured at
year 15: age, gender, race, high- and low-density lipo-
proteins, triglycerides, smoking, blood pressure stage
[15], presence of metabolic syndrome [16], C-reactive
protein, waist circumference, alcohol use, creatinine, and
serum albumin concentration. These factors have been
assessed in previous studies of hyperuricemia and cardi-
ovascular risk and therefore were included in the pre-
sent analyses. In our primary analyses, all of these
covariates were included in the model, regardless of the
statistical significance of each. Subsequent confirmatory
analyses deployed backward selection methods (with P <
0.20 as the cutoff) to derive a more parsimonious model.
The second objective of the analyses was to test the
hypothesis that, among those with CAC, Agatston
scores will be directly proportional to sUA concentra-
tion. The distribution of these scores was skewed, with
numerous outliers. Hence, in these analyses, we used
ordinary least square (OLS) regression models in which
the dependent variable was the log-transformed Agat-
ston score (log2 [CAC + 1]). For these OLS regression
analyses, we excluded all participants who had an Agat-
ston score of zero.
In all regression models, we explored the data for the
presence of statistical interaction between gender, race,
and sUA. Model fit was verified by using the Hosmer-
Lemeshow method [17]. Data analyses were performed
by using SAS
® (SAS Institute Inc., Cary, NC, USA).
Results
Of the 5,115 participants at baseline, 3,671 participated
in the examination at year 15. Among these, 1,173 were
excluded as they met the study exclusion criteria. Over-
all, there were 2,498 participants (1,211 men and 1,287
women) available for analyses. Table 1 shows the char-
acteristics of these participants. Higher sUA concentra-
tions were associated with greater prevalence of
cardiovascular risk factors, metabolic syndrome, and
high Framingham risk score (Table 1). Fewer than 20
participants had a self-reported history of probable or
definite gout and these could not be independently veri-
fied. None of the study population was using urate-low-
ering medications such as allopurinol, probenecid,
sulfinpyrazone, or losartan.
The mean ± standard deviation of sUA concentration
was 345 ± 77 μmol/L (5.8 ± 1.3 mg/dL) for men and 238 ±
65 μmol/L (4.0 ± 1.1 mg/dL) for women (P < 0.001). sUA
was distributed normally among men and women, whites,
and African-Americans. The proportions of participants
with sUA of greater than 416 μmol/L (7.0 mg/dL) were
8.4% (n = 211) overall, 16.6% (n = 201) among men, and
0.8% (n = 10) among women. The men had a significantly
worse overall cardiovascular risk profile than women
(Table 1). sUA concentrations were correlated with male
gender (correlation coefficient of 0.6; P < 0.01) and Fra-
mingham risk score (0.52; P < 0.01) but were only modestly
associated with other known cardiovascular risk factors (all
correlation coefficients of less than 0.3; P < 0.05). C-reac-
tive protein levels were not correlated with sUA (P =0 . 2 0 ) .
The majority (90.5%, n = 2,260) of participants had no
detectable CAC. Overall, 9.5% (n = 238) of participants
had an Agatston score of greater than 0, 6.3% (n =1 5 8 )
had an Agatston score of greater than 10, and 1.4% (n =
34) had an Agatston score of greater than 100. As
expected in a cohort free of clinical CAD, relatively few
participants had an Agatston score of greater than 400
(n = 4). Among those with any CAC, mean scores were
h i g h e ri nm e nt h a ni nw o m e n( 7 5 . 0v e r s u s6 0 . 8 ;W i l -
coxon rank sum test P =0 . 7 7 )a n di nw h i t e st h a ni n
African-Americans (71.6 versus 70.0; P = 0.19), but
these findings were not statistically significant.
At each quartile of sUA, men had a greater prevalence
of CAC than women (Figure 1). However, the preva-
lence of CAC increased with increasing sUA in both
g e n d e r s ,a n dt h eh i g h e s tq u a r t i l eh a da l m o s tt w ot i m e s
the prevalence compared with the lowest (odds ratio
[OR] 1.87, CI 1.19 to 2.93) (Table 2).
In the bivariate logistic regressions in which presence
or absence of CAC was the dependent variable, the
highest quartile of sUA concentrations (greater than 393
μmol/L [6.6 mg/dL] for men and greater than 274
μmol/L [4.6 mg/dL] for women) had an OR of greater
than 2.0 among both men and women, regardless of the
Agatston score cutoff used to define CAC (Table 3).
We developed parallel multivariable logistic regression
models that included all of the risk factors of interest
(age, gender, race, high- and low-density lipoproteins,
triglycerides, smoking, blood pressure class, presence of
metabolic syndrome, C-reactive protein, waist circum-
ference, alcohol use, creatinine, and serum albumin con-
centration) in the model. Data were pooled for men and
women, and gender-specific stratification for quartiles of
sUA was used after we established that there was no
statistically significant interaction between gender and
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Page 3 of 8Table 1 Characteristics of study population by gender and serum uric acid quartile
Women (n = 1,287) Men (n = 1,211)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Quartile 1 Quartile 2 Quartile 3 Quartile 4
sUA range, μmol/L [mg/dL] 77-196 [1.3-3.3] 196-226 [3.3-3.8] 232-274 [3.9-4.6] 280-636 [4.7-10.7] 155-291 [2.6-4.9] 297-333 [5.0-5.6] 339-393 [5.7-6.6] 399-690 [6.7-11.6]
Age, years 40.1 (3.8) 40.1 (3.6) 40.3 (3.6) 40.5 (3.8) 40.1 (3.6) 39.8 (3.5) 40.4 (3.5) 40.4 (3.6)
African-American 43.5% 42.6% 46.5% 57.5% 42.7% 37.4% 42.5% 43.2%
Body mass index, kg/m
2 24.8 (4.7) 27.2 (6.2) 29.6 (6.8) 33.1 (7.2) 26.1 (3.8) 27.4 (4) 28.1 (4.5) 30.1 (4.6)
Alcohol, mL/day 6.2 (10) 5.7 (11.8) 9 (32.7) 9.1 (22) 13.3 (35.4) 14.2 (25.1) 16.2 (24.4) 20.3 (35.1)
Smokers 36.6% 39.7% 38% 46.2% 35.3% 39.4% 39.3% 40.2%
Systolic BP, mm Hg 107 (12.5) 109.3 (14) 112.4 (15.3) 115.5 (16.3) 111.7 (11.2) 114.8 (13.5) 115.4 (12.9) 118.3 (14.7)
Diastolic BP, mm Hg 69.6 (10.1) 71.5 (10.2) 73.3 (10.9) 75.9 (12.6) 73.3 (9.2) 76.3 (11) 76.8 (10.2) 79.2 (12.1)
Serum fasting glucose, mmol/L
[mg/dL]
4.45 (0.40) [80.2
(7.2)]
4.48 (0.43) [80.7
(7.7)]
4.5 (0.45) [81.1
(8.1)]
4.7 (0.53) [84.3
(9.5)]
4.7 (0.46) [84 (8.3)] 4.8 (0.53) [85.7
(9.6)]
4.8 (0.52) [86.4
(9.4)]
4.9 (0.54) [88.8 (9.7)]
Serum HDL-C, mmol/L [mg/dL] 1.54 (0.33) [59.7
(12.8)]
1.44 (0.35) [55.5
(13.5)]
1.45 (0.36) [56
(14.1)]
1.32 (0.37) [51
(14.4)]
1.24 (0.33) [48
(12.9)]
1.19 (0.32) [45.9
(12.4)]
1.14 (0.31) [43.9
(11.8)]
1.10 (0.33) [42.4
(12.6)]
Serum LDL-C, mmol/L [mg/dL] 2.72 (0.73) [105.1
(28.2)]
2.74 (0.74) [105.9
(28.7)]
2.80 (7.7) [108.4
(29.8)]
3.01 (0.79) [116.3
(30.6)]
2.87 (0.74) [110.9
(28.5)]
3.12 (0.81) [120.5
(31.5)]
3.19 (0.95) [123.5
(36.6)]
3.23 (0.92) [125
(35.7)]
Serum triglycerides, mmol/L
[mg/dL]
0.78 (0.38) [68.8
(33.8)]
0.89 (0.44) [78.7
(39.1)]
0.95 (0.52) [84.5
(45.8)]
1.27 (0.80) [112.6
(70.7)]
1.01 (0.67) [89.8
(59.7)]
1.26 (0.76) [111.5
(67.4)]
1.52 (1.87) [135
(165.7)]
1.86 (1.76) [164.8
(156.1)]
Serum creatinine, μmol/L [mg/
dL]
79.6 (8.8) [0.9 (0.1)] 79.6 (8.8) [0.9 (0.1)] 79.6 (8.8) [0.9
(0.1)]
79.6 (8.8) [0.9 (0.1)] 97.2 (8.8) [1.1 (0.1)] 97.2 (8.8) [1.1 (0.1)] 97.2 (17.7) [1.1
(0.2)]
97.2 (17.7) [1.1 (0.2)]
Waist circumference, cm 76.6 (10.1) 81.6 (12.1) 86.3 (13.1) 94 (14.1) 87.8 (9.5) 91.8 (9.6) 93.5 (11) 98.4 (10.9)
eGFR, abbreviated MDRD 87.2 (15.1) 85.6 (15.5) 83.9 (14.2) 82.7 (15.2) 89.9 (13.6) 88.3 (14.1) 87.1 (19.3) 85.6 (16.1)
Framingham risk score -4.8 (4.1) -3.7 (4.3) -3.3 (4.4) -1.4 (4.3) 1.1 (2.2) 1.8 (2.4) 2.3 (2.3) 2.7 (2.4)
C-reactive protein, mg/dL 1.5 (2.9) 1.5 (1.7) 1.6 (2.9) 1.8 (1.7) 1.7 (2.9) 1.8 (2.0) 2.0 (2.5) 2.1 (2.5)
Data are presented as range, mean (standard deviation), or percentage. BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; MDRD, modification of diet in renal disease; sUA, serum uric acid.
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8the correlation between sUA concentration and CAC
(Table 2). Although these models differed in the defini-
tion of subclinical atherosclerosis and in the stratifica-
tion strategy for sUA, all models showed that the
highest quartile of sUA concentration was associated
with significantly higher risk for subclinical atherosclero-
sis. In both multivariable regression models, each unit
increase in sUA concentration was associated with an
OR of 1.23 (CI 1.09 to 1.39) for subclinical atherosclero-
sis. The findings were replicated in backward stepwise
selection models that eliminated those factors that were
not significant individually as well as those in which an
alternate stratification strategy for sUA was used (data
not shown).
The last set of analyses focused on the association
between sUA concentration and the severity of CAC.
These analyses included only those subjects who had
Agatston score of greater than zero (n = 238). Although
the Agatston scores were higher among those with higher
sUA concentrations (Figure 2), bivariate correlation ana-
lyses showed that the association was not strong (correla-
tion coefficient of 0.13). However, in multivariable OLS
regression models, each unit increase in sUA concentra-
tion was associated with a significant increase in the log-
transformed Agatston score (beta coefficient of 0.288,
95% CI 0.078 to 0.498; P = 0.008; R
2 = 0.197%). In other
words, there was an approximately 22% increase in Agat-
ston score for each unit increase in sUA. When examined
separately for each gender, this association persisted for
men (beta coefficient of 0.300, CI 0.078 to 0.522) and
women (beta coefficient of 0.318, CI -0.502 to 1.138) but
was statistically significant only in the former (P = 0.009).
Discussion
The association between hyperuricemia and the pre-
sence of subclinical atherosclerosis has not previously
been studied in a cohort of young adults with no risk
factors for CAD. Our study found a direct correlation
between the prevalence and severity of CAC and sUA
concentration in both men and women. This supports
the hypothesis that uric acid may be involved in the
pathologic process of atherosclerosis independently of
conventional risk factors.
Table 2 Crude risk of increasing serum concentrations of uric acid
Odds ratio for outcome
Serum uric acid
concentration,
μmol/L [mg/dL]
Agatston score
>0 vs. Agatston
score = 0
Agatston score >10 vs. Agatston score <10
Men (n = 1,211)
Quartile 1 155-291 [2.6-4.9] 1 1
Quartile 2 297-333 [5.0-5.6] 1.17 (0.71-1.95) 1.21 (0.65-2.23)
Quartile 3 339-393 [5.7-6.6] 1.56 (0.96-2.54) 1.62 (0.91-2.91)
Quartile 4 399-690 [6.7-11.6] 2.07 (1.30-3.31) 2.08 (1.19-3.67)
Women (n = 1,287)
Quartile 1 77-196 [1.3-3.3] 1 1
Quartile 2 196-226 [3.3-3.8] 1.50 (0.66-3.38) 1.49 (0.52-4.22)
Quartile 3 232-274 [3.9-4.6] 1.44 (0.65-3.23) 1.5 (0.54-4.17)
Quartile 4 280-636 [4.7-10.7] 2.47 (1.17-5.22) 2.93 (1.15-7.49)
Overall (n = 2,498)
Quartile 1 77-291 [1.3-4.9] 1 1
Quartile 2 196-333 [3.3-5.6] 1.25 (0.81-1.91) 1.27 (0.75-2.15)
Quartile 3 232-393 [3.9-6.6] 1.47 (0.98-2.22) 1.54 (0.93-2.54)
Quartile 4 280-690 [4.7-11.6] 2.11 (1.42-3.12) 2.24 (1.39-3.60)
P<0.001
P=0.04
SUA Range for Men:
SUA Range for Women:
2.6-4.9
1.3-3.3
5.0-5.6
3.3-3.8
5.7-6.6
3.9-4.6
6.7-11.6
4.7-10.7
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Figure 1 Prevalence of any coronary artery calcification
(Agatston score >0) by serum uric acid concentration among
participants in the CARDIA study cohort at year 15. A detailed
description of these patients (1,211 men and 1,287 women) is
provided in Table 1. P values are for trend test. CAC, coronary artery
calcification; CARDIA, Coronary Artery Risk Development in Young
Adults; SUA, serum uric acid.
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Page 5 of 8Uric acid is a ubiquitous antioxidant in the blood [18].
Abnormally high serum concentrations of uric acid indi-
cate oxidative stress, endothelial dysfunction, and slow
coronary artery blood flow [19,20]. Elevated sUA con-
centration signifies a milieu with high oxidative stress
and potentially indicates a vascular pathologic process
such as atherosclerosis [21]. An association between
hyperuricemia and CAC has been observed in previous
studies involving patients with underlying risk factors
for CAD such as type 1 diabetes, longstanding hyperten-
sion, or metabolic syndrome [22-25]. Importantly, a
cross-sectional analysis of 443 individuals with type 1
diabetes suggested that the chances of progressive CAC
were proportional to the magnitude of sUA concentra-
tion [22]. Another study involved older age groups
compared with our cohort but also found that the corre-
lation between uric acid and CAC was evident among
men and women and in similar magnitude [13]. In the
INSIGHT (International Nifedipine Study Intervention
as Goal for Hypertension Therapy) study, in which CAC
was measured in hypertensive patients who were older
than 55 years of age and who had at least one more
major cardiovascular risk factor, those with a total cor-
onary calcium score (TCS) of greater than zero had a
slightly higher sUA concentration compared with those
with a TCS of zero (333 ± 89 versus 315 ± 83 μmol/L
[5.6 ± 1.5 versus 5.3 ± 1.4 mg/dL]; P = 0.03) [23]. How-
ever, other studies, including the GENOA (Genetic Epi-
demiology Network of Arteriopathy) study on sibships
with at least two members with diagnosed hypertension,
did not show an association between uric acid concen-
tration and the presence or severity of CAC after adjust-
ment for conventional risk factors [25-27]. In addition,
the National Heart, Lung and Blood Institute (NHLBI)
Family Heart Study did not find a significant relation-
ship between hyperuricemia and CAC in either gender
[28]. Among those who underwent coronary angiogra-
phy for suspected CAD, sUA concentration of greater
than 416 μmol/L (7.0 mg/dL) was associated with stable
plaques without evidence of remodeling. The authors
i n t e r p r e tt h i sa ss u g g e s t i n gt h a tu r i ca c i di sam a r k e ro f
atherosclerosis rather than a pathogenic mediator
[13,29].
Coronary atherosclerosis is less likely to be associated
with calcification among women compared with coron-
ary atherosclerosis with a similar degree of lumen nar-
rowing in men [30]. In the CARDIA study cohort, the
prevalences of CAC were approximately 15% among
men and approximately 5% among women overall [14].
This could be because younger women may be ‘resis-
tant’ to atheroma growth [31].
Gender might be an important effect modifier in the
association between hyperuricemia and CAC because of
differences in (a) the distribution of sUA and (b) the
prevalence of CAC. Iribarren and colleagues [32] ana-
lyzed data from the Atherosclerosis Risk in Commu-
nities (ARIC) study and concl u d e dt h a ta na s s o c i a t i o n
between sUA and cardiovascular risk is evident in men
but not women. In contrast, a similar study by Ishizaka
and colleagues [33] reported that gender was not a fac-
tor. Since the prevalences of hyperuricemia and CAC
are both lower among women, a greater sample size
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Figure 2 Relationship between burden of coronary artery
calcification (unmodified Agatston score) and serum uric acid
concentrations. These analyses included only those subjects who
had an Agatston score of greater than zero (n = 238). P values are
for trend test. SUA, serum uric acid.
Table 3 Adjusted relative risk for subclinical atherosclerosis according to strata of serum uric acid concentrations
Odds ratio for outcome
Serum uric acid concentration, μmol/L
[mg/dL]
Agatston score >0 vs. Agatston
score = 0
Agatston score >10 vs. Agatston
score <10
Quartile of serum uric acid
a
Quartile 1 77-291 [1.3-4.9] 1 1
Quartile 2 196-333 [3.3-5.6] 1.24 (0.78-1.97) 1.26 (0.72-2.22)
Quartile 3 232-393 [3.9-6.6] 1.42 (0.9-2.24) 1.50 (0.87-2.58)
Quartile 4 280-690 [4.7-11.6] 1.87 (1.19-2.93) 1.91 (1.12-3.26)
Adjusted for the effects of age, gender, race, high- and low-density lipoproteins, triglycerides, smoking, blood pressure class, presence of metabolic syndrome,
C-reactive protein, waist circumference, alcohol use, creatinine, and serum albumin concentration. No participants had diabetes or renal impairment.
aMen and
women were classified into quartiles by gender-specific cutoff numbers and were subsequently pooled.
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icemia-CAC association. We defined quartiles separately
for men and women prior to pooling. Statistical tests of
gender-sUA interaction were not significant in our data.
In gender-specific analyses, the direction and magnitude
of risk among women were similar to those among
men; however, the standard errors were wide because of
the lower power for precise estimates.
The major strength of our community-based study is
the generalizability of our results to young adults, includ-
ing men, women, African-Americans, and whites. All of
the studies described earlier were performed among
patients with greater-than-normal cardiovascular risk,
such as those with hypertension, diabetes, metabolic syn-
drome, psoriasis, or renal disease [13,21,23,26-29].
The primary limitation of this study was the cross-sec-
tional nature of data analysis. Survivor bias can affect
cross-sectional data analyses in that those with more
severe disease die prior to the time point of analysis;
however, this is not a major consideration in the CAR-
DIA study as the main cause of mortality in the first 16
years was non-cardiovascular in the vast majority of
patients (117/127 deaths out of 5,115 enrollees). Our
future studies will examine the rate of progression of
CAC over time among patients with hyperuricemia or
gout or both. Gouty arthritis has been associated with
CAD among middle-aged men [34], but our study had
too few participants with gout (n <20) to allow a formal
analysis. A larger number of women would have enabled
separate analyses with respect to use of exogenous hor-
mones and menstrual status. Owing to the design of our
study, there was relatively little heterogeneity with
respect to age (approximately 12 years), precluding an
analysis of impact of age on the hyperuricemia-CAC
association. However, in our analyses, age was not sig-
nificantly associated with sUA concentration. sUA con-
centration is known to vary with time of day and recent
dietary intake and possibly with physical exertion, intro-
ducing ‘random noise’ in sUA data. Unless sUA
increases due to such variables can be shown to occur
preferentially among those with higher CAC scores, this
issue cannot explain our findings. As in all other epide-
miological studies, unmeasured covariates could have
caused residual confounding in our study as well.
Conclusions
We have shown for the first time that sUA is associated
with the presence and severity of CAC in young healthy
adults, implicating a potential role of uric acid in the
pathogenesis of subclinical atherosclerosis. Our data are
consistent with the growing body of literature that
implicates the vascular injury associated with hyperuri-
cemia - both macrovascular and microvascular [2,22,35].
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